Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H1 2018

  • ID: 4537870
  • Report
  • 390 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • AbbVie Inc
  • Bharat Biotech Ltd
  • Helix BioMedix Inc
  • Meiji Seika Pharma Co Ltd
  • Oragenics Inc
  • Sorrento Therapeutics Inc
  • MORE
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H1 2018, provides an overview of the Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline landscape.

MRSA infections that are acquired by persons who have not been recently (within the past year) hospitalized or had a medical procedure (such as dialysis, surgery, catheters) are known as community-acquired MRSA (CA-MRSA) infections. Risk factors are hemodialysis, weakened immune system, admission to hospitals and wounds. Symptoms include skin rashes, fatigue, chest pain, fever and swelling. MRSA can be managed by the use of antibiotics and by maintaining hygienic conditions.

Report Highlights:

This latest pipeline guide Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 8, 15, 11, 2, 71, 32 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 30 and 24 molecules, respectively.

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie Inc
  • Bharat Biotech Ltd
  • Helix BioMedix Inc
  • Meiji Seika Pharma Co Ltd
  • Oragenics Inc
  • Sorrento Therapeutics Inc
  • MORE
Introduction

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Overview

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Therapeutics Development

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Therapeutics Assessment

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Companies Involved in Therapeutics Development

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Drug Profiles

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Discontinued Products

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AbbVie Inc, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Absynth Biologics Ltd, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Actelion Pharmaceuticals Ltd, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Adenium Biotech ApS, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Alchemia Ltd, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Allergan Plc, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AmpliPhi Biosciences Corp, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Antibiotx ApS, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Aphios Corp, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Aridis Pharmaceuticals LLC, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Atriva Therapeutics GmbH, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Bavarian Nordic A/S, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Bharat Biotech Ltd, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by C3J Therapeutics Inc, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Cadila Pharmaceuticals Ltd, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Citius Pharmaceuticals Inc, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by ContraFect Corp, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Crestone Inc, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by CrystalGenomics Inc, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Daiichi Sankyo Co Ltd, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Debiopharm International SA, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by DesignMedix Inc, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Destiny Pharma Ltd, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Emergent BioSolutions Inc, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by GangaGen Inc, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Helix BioMedix Inc, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Helperby Therapeutics Group Ltd, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Hsiri Therapeutics LLC, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Ildong Pharmaceutical Co Ltd, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Insmed Inc, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Instituto Biomar SA, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by iNtRON Biotechnology Inc, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by ioGenetics Inc, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by KBP BioSciences Co Ltd, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Lakewood-Amedex Inc, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Lead Discovery Center GmbH, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by LegoChem Biosciences Inc, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Madam Therapeutics BV, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Meiji Seika Pharma Co Ltd, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Melinta Therapeutics Inc, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Merck & Co Inc, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Microbiotix Inc, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by MicuRx Pharmaceuticals Inc, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Nabriva Therapeutics plc, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Nemus Bioscience Inc, H1 2018

List of Figures

Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AbbVie Inc
  • Absynth Biologics Ltd
  • Actelion Pharmaceuticals Ltd
  • Adenium Biotech ApS
  • Alchemia Ltd
  • Allergan Plc
  • AmpliPhi Biosciences Corp
  • Antibiotx ApS
  • Aphios Corp
  • Aridis Pharmaceuticals LLC
  • Atriva Therapeutics GmbH
  • Bavarian Nordic A/S
  • Bharat Biotech Ltd
  • C3J Therapeutics Inc
  • Cadila Pharmaceuticals Ltd
  • Citius Pharmaceuticals Inc
  • ContraFect Corp
  • Crestone Inc
  • CrystalGenomics Inc
  • Daiichi Sankyo Co Ltd
  • Debiopharm International SA
  • DesignMedix Inc
  • Destiny Pharma Ltd
  • Emergent BioSolutions Inc
  • GangaGen Inc
  • Helix BioMedix Inc
  • Helperby Therapeutics Group Ltd
  • Hsiri Therapeutics LLC
  • Ildong Pharmaceutical Co Ltd
  • Insmed Inc
  • Instituto Biomar SA
  • iNtRON Biotechnology Inc
  • ioGenetics Inc
  • KBP BioSciences Co Ltd
  • Kyorin Pharmaceutical Co Ltd
  • Lakewood-Amedex Inc
  • Lead Discovery Center GmbH
  • LegoChem Biosciences Inc
  • Madam Therapeutics BV
  • Meiji Seika Pharma Co Ltd
  • Melinta Therapeutics Inc
  • Merck & Co Inc
  • Microbiotix Inc
  • MicuRx Pharmaceuticals Inc
  • Nabriva Therapeutics plc
  • Nemus Bioscience Inc
  • Novabiotics Ltd
  • NovaDigm Therapeutics Inc
  • Novalex Therapeutics Inc
  • Novan Inc
  • NovoBiotic Pharmaceuticals LLC
  • Oragenics Inc
  • Ovensa Inc
  • Oxford Drug Design Ltd
  • Pfizer Inc
  • Phico Therapeutics Ltd
  • PolyPid Ltd
  • Prommune Inc
  • Recce Ltd
  • Savara Inc
  • Sealife PHARMA GMBH
  • Sorrento Therapeutics Inc
  • Taejoon Pharm Co Ltd
  • TAXIS Pharmaceuticals Inc
  • Telephus Medical LLC
  • Tetraphase Pharmaceuticals Inc
  • Therapeutic Systems Research Laboratories Inc
  • Theravance Biopharma Inc
  • Trellis Bioscience Inc
  • Valevia UK Ltd
  • Venus Medicine Research Center
  • VLP Biotech Inc
  • Wockhardt Ltd
  • XBiotech Inc
  • Yungjin Pharm Co Ltd
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll